This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643597.
ClinicalTrials.gov Identifier:
NCT02527629
News
Update on decellularized homografts for double semilunar valve replacement
Bobylev et al published an update on the Hannover Medical School experience in simultaneous double semilunar valve replacement in congenital heart disease. Decellularized homografts were used for double valve replacement as well...
Long decellularized valved aortic homografts restore normal hemodynamics
A 4D-Flow CMR study on decellularized allografts for extended aortic valve replacement was recently published within the European Journal of Cardiothoracic Surgery. Cvitkovic et al. demonstrate within this publication near...
Newly developed method helps to quantify the residual immunogenic potential of decellularized human heart valves
Dot-blot techniques demonstrate highly individual immune response towards decellularized homografts - Results published Open Access in the European Journal of Cardio-Thoracic-Surgery
Welcome to ARISE
65,000 aortic valve replacements (AVR) are performed in Europe each year to treat acquired and congenital aortic valve diseases. Current AVR options are, however, limited for young patients - especially female patients - and those unwilling to accept life-long medical anticoagulation with its inherent risks. None of the currently available prostheses for AVR is tailored toward the individual patient or allows for individual regeneration. The ARISE project will bridge this therapeutic gap in a clinical study to determine the feasibility, safety and efficacy of regenerative heart valves for aortic valve replacement.